Laparoscopic Ileal Interposition and Weight Regain
Launched by RIO DE JANEIRO STATE UNIVERSITY · Jun 26, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a surgical procedure called ileal interposition as a way to help people who have regained weight after an earlier weight-loss surgery known as Roux-en-Y gastric bypass. The study will look at how well this new procedure works in helping participants lose weight again, improve their body composition (the amount of fat versus muscle), and enhance their overall quality of life. Researchers will also measure various health markers related to metabolism and inflammation to see how this surgery impacts patients’ health.
To be eligible for the trial, participants need to have had the Roux-en-Y surgery at least three years ago and have lost between 60-80% of their excess weight, but are now experiencing significant weight regain (at least 60%). Candidates must have a body mass index (BMI) of 40 or higher, or 35 with related health issues. Participants can expect a thorough evaluation by a team of medical professionals to ensure that the surgery is suitable for them. It's important to note that certain medical conditions or personal circumstances, like severe mental health issues or substance dependency, may prevent someone from joining the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients submitted to initial laparoscopic after initial Roux-en-Y gastric bypass for at least 3 years
- • Loss of excess weight between 60 to 80%
- • Rate of weight regain ≥60%
- • Body mass index ≥ 40 kg/m2 or ≥ 35 kg/m2, with at least 2 comorbidities associated with obesity
- • Present a previous evaluation by the multidisciplinary team with a favorable opinion of the revision surgery.
- Exclusion Criteria:
- • Active chemical dependency on alcohol and/or illicit drugs
- • Severe psychotic or depressive disorder or history of suicide attempts in the last 12 months
- • Eating behavior disorder (uncontrolled)
- • Secondary causes of obesity
- • Pregnancy
- • Severe organ failure
- • Active neoplastic
- • Infectious or inflammatory disease
- • Severe coagulopathy
- • High anesthetic-surgical risk
- • Intellectual inability
- • Lack of preoperative follow-up
About Rio De Janeiro State University
Rio de Janeiro State University (UERJ) is a prominent academic institution in Brazil, recognized for its commitment to advancing research and education across various disciplines, including health sciences. As a clinical trial sponsor, UERJ leverages its extensive resources and expertise to facilitate innovative research initiatives aimed at improving healthcare outcomes. With a focus on interdisciplinary collaboration, the university engages in cutting-edge studies that address critical health challenges, ensuring adherence to ethical standards and regulatory requirements. UERJ's dedication to fostering scientific inquiry and community health makes it a vital contributor to the landscape of clinical research in Brazil and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rio De Janeiro, , Brazil
Patients applied
Trial Officials
Luiz Guilherme Kraemer-Aguiar, PhD
Principal Investigator
State University of Rio de Janeiro
Paulo Roberto G Falcão Leal, MD
Principal Investigator
State University of Rio de Janeiro
Karynne G Grutter Lopes, PhD
Principal Investigator
State University of Rio de Janeiro
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported